OncoMatch/Clinical Trials/NCT06610825
Castrate Resistant Prostate Cancer Enhertu Therapy
Is NCT06610825 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Enhertu for prostate cancer metastatic.
Treatment: Enhertu — Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: HER2 (ERBB2) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen deprivation therapy
Documented progression on androgen deprivation
Must have received: novel hormonal agent
Documented progression on...novel hormonal agents
Cannot have received: HER2-targeted therapy
Previous exposure to HER2 targeted therapy
Lab requirements
Blood counts
Adequate Organ and Bone Marrow function; Adequate Blood Clotting function
Kidney function
Adequate Renal function
Liver function
Adequate Hepatic function
Cardiac function
LVEF at least 50%
Adequate Blood Clotting function; Adequate Organ and Bone Marrow function; Adequate Renal function; Adequate Hepatic function; LVEF at least 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington DC VAMC · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify